Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
Information source: H. Lee Moffitt Cancer Center and Research Institute
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Myelodysplastic Syndrome; MDS
Intervention: Prednisone (Drug); Lenalidomide (Drug)
Phase: Phase 2
Sponsored by: H. Lee Moffitt Cancer Center and Research Institute
Official(s) and/or principal investigator(s):
Rami Komrokji, M.D., Principal Investigator, Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Jennifer Paleveda, Phone: 813-745-5413, Email: email@example.com
The purpose of this research is to evaluate the use of lenalidomide and prednisone in people
with Myelodysplastic Syndrome (MDS).
Lenalidomide is a drug that alters the immune system and it may also interfere with the
development of tiny blood vessels that help support tumor growth. Therefore, in theory, it
may reduce or prevent the growth of cancer cells. Lenalidomide is approved by the U. S. Food
and Drug Administration (FDA) for the treatment of specific types of myelodysplastic
syndrome (MDS) and in combination with dexamethasone for people with multiple myeloma (MM)
who have received at least 1 prior therapy. MDS and MM are cancers of the blood. It is
currently being tested in a variety of cancer conditions. As it is being used in this study
it is considered an investigational use. An "investigational use" is a use that is being
tested and is not approved by the FDA.
Prednisone is approved by the FDA to treat numerous conditions. In addition, prednisone is
approved by the FDA to treat Low or Intermediate-1 IPSS Risk, non-del (5q) MDS.
"Study drug" refers to the combination of lenalidomide and prednisone.
Official title: A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of Participants With Erythroid Response
Secondary outcome: Number of Participants With Adverse Events (AEs)
After the screening test results come back, then participants and the study doctor and study
staff will decide whether or not the patient should be in the study. Once it has been
determined, patients may enter the study and if they agree, then patients will begin the
When enrolled into this study, patients will be given study drug for 6 cycles (24 weeks).
Each cycle is 28 days (4 weeks).
Patients will be given a prescription for 10 mg/day of lenalidomide to take orally (by
mouth) on days 1 - 28 of cycles 1-6. Dosing will be in the morning at approximately the same
time each day. Prescriptions must be filled within 7 days.
If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day.
If it is missed for the entire day, it should not be made up.
The prednisone dose will be as follows:
- 30 mg by mouth daily, days 1-28 of cycle 1
- 20 mg by mouth daily, days 1-28 of cycle 2
- 10 mg by mouth daily, days 1-28 of cycle 3
- 10 mg by mouth every other day on days 1-28 of cycles 4-6
- 5 mg by mouth every other day for responders beyond cycle 6
Minimum age: 18 Years.
Maximum age: N/A.
- Understand and voluntarily sign an informed consent form
- Age ≥ 18 years at the time of signing the informed consent form
- Able to adhere to the study visit schedule and other protocol requirements
- Documented diagnosis of MDS according Word Health Organization (WHO) that meets
International Prognostic Scoring System (IPSS) criteria for Low- to
Intermediate-1-risk disease or non-proliferative (white blood count [WBC] <
13,000/uL) chronic myelomonocytic leukemia (CMML) and MDS/myeloproliferative
- Absence of a chromosome 5q deletion by metaphase cytogenetics or fluorescent in situ
hybridization (FISH) analysis
- Red blood cell (RBC) transfusion-dependent anemia defined as having received ≥4
transfusions of RBCs for hemoglobin (Hgb) ≤ 9. 0 g/dl within 56 days of randomization
or symptomatic anemia (Hgb ≤ 9. 0 g/dl)
- No response or progression on prior treatment with epoetin alpha (> 40,000 U/wk x 6),
darbepoetin alpha (≥ 500 mcg q 3 wk x 2) or serum erythropoietin (EPO) concentration
≥ 500 mU/ml
- All previous cancer therapy, including radiation, hormonal therapy and surgery, must
have been discontinued at least 4 weeks prior to treatment in this study.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 at study entry
- Laboratory test results within these ranges: Absolute neutrophil count ≥ 500 /mm³;
Platelet count ≥ 50,000 /mm³; Creatinine Clearance > 60 mL/min by Cockcroft-Gault
formula; Total bilirubin ≤ 1. 5 mg/dl; aspartic transaminase (AST)and alanine
transaminase (ALT) ≤ 2 x upper limit of normal (ULN).
- Disease free of prior malignancies for ≥ 3 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix
- Must be registered into the mandatory RevAssist® program, and be willing and able to
comply with the requirements of RevAssist®.
- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 milli-international units per
milliliter (mIU/mL) within 10 - 14 days prior to and again within 24 hours of
prescribing lenalidomide (prescriptions must be filled within 7 days) and must either
commit to continued abstinence from heterosexual intercourse or begin TWO acceptable
methods of birth control, one highly effective method and one additional effective
method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP
must also agree to ongoing pregnancy testing. Men must agree to use a latex condom
during sexual contact with a FCBP even if they have had a successful vasectomy.
- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the patient from signing the informed consent form.
- Pregnant or breast feeding. (Lactating females must agree not to breast feed while
- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.
- Use of any other experimental drug or therapy within 28 days of baseline
- Known hypersensitivity to thalidomide
- The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or similar drugs or history of desquamating (blistering) rash
while taking thalidomide
- Any prior use of lenalidomide
- Concurrent use of other anti-cancer agents or treatments
- Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B
- Proliferative CMML (WBC ≥13,000/μL)
- MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for
malignant or autoimmune diseases
- Prior ≥ grade-2 National Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) allergic reaction to thalidomide
- Clinically significant anemia due to factors such as iron, B12 or folate
deficiencies, autoimmune or hereditary hemolysis or gastrointestinal bleeding
- Known HIV-1 positivity
- Chromosome 5q deletion
- Documented thromboembolic event within the past 3 years
Locations and Contacts
Jennifer Paleveda, Phone: 813-745-5413, Email: firstname.lastname@example.org
University of Florida Shands Cancer Center, Gainesville, Florida 32610, United States; Recruiting
Leslie Pettiford, Phone: 352-243-6839, Email: email@example.com
Christopher Cogle, M.D., Principal Investigator
John Hiemenz, M.D., Sub-Investigator
Jack Hsu, M.D., Sub-Investigator
William May, M.D., Sub-Investigator
Jan Moreb, M.D., Sub-Investigator
Maxim Norkin, M.D., Sub-Investigator
John Wingard, M.D., Sub-Investigator
Baldeep Wirk, M.D., Sub-Investigator
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States; Recruiting
Nancy Hillgruber, Phone: 813-745-2071, Email: firstname.lastname@example.org
Rami Komrokji, M.D., Principal Investigator
Paul Chervenick, M.D., Sub-Investigator
Darcie Deaver, ARNP, Sub-Investigator
Jeffrey Lancet, M.D., Sub-Investigator
Alan List, M.D., Sub-Investigator
Hussain Saba, M.D., Ph.D., Sub-Investigator
Sara Tinsley, ARNP, Sub-Investigator
Kenneth Zuckerman, M.D., Sub-Investigator
Martine Extermann, M.D., Sub-Investigator
Eric Padron, M.D., Sub-Investigator
Moffitt Cancer Center Clinical Trials website
Starting date: April 2010
Last updated: November 1, 2012